Table 2.

Outcomes of 47 patients treated with cord blood transplantation who received fludarabine, melphalan, thiotepa and ATG conditioning.

	Overall (N=47)		Adult (N=30)		Pedi (N=17)
Engrafted, n (%)	43 (91)		27 (90)		16 (94)
Days to ANC 500 (median, (range))	22	(6-115)	21	(6-45)	22	(11-115)
Days to PLT 20,000 (median, (range))	35	(25-157)	35	(27-134)	34	(25-157)
	(%)	95% CI	(%)	95% CI	(%)	95% CI	*HR	95% CI	p
aGVHD, %CI
II-IV	40%	28-57	36%	19-55	47%	28-78	0.8	0.3-1.9	0.6
III-IV	13%	6-28	14%	6-35	12%	3-43	1.2	0.2-6.9	0.8
cGVHD, %CI	34%	22-51	43%	28-66	18%	6-51	3.6	1.0-1.3	0.05
NRM, %CI
100 days	11%	5-24	13%	5-33	6%	1-39	2.2	0.2-20	0.5
1 year	28%	18-44	30%	17-52	25%	11-60	1.3	0.4-4.3	0.6
2 years	40%	28-58	43%	29-65	33%	16-69	1.8	0.6-5.6	0.3
Last f/up	40%	28-58	43%	29-65	33%	16-69	1.5	0.5-4.3	0.4
Disease progression, %CI
100 days	0%	NA	0%	NA	0%	NA	NA	NA	NA
1 year	20%	11-35	20%	10-41	18%	6-49	1.2	0.3-4.9	0.8
2 years	24%	15-41	28%	15-50	18%	6-49	1.7	0.5-6.6	0.4
Last f/up	32%	19-55	40%	23-72	18%	6-49	2	0.5-7.6	0.3
Survival, %KM
100 days	85%	71-93	83%	64-93	88%	61-97	1.4	0.3-7.2	0.7
1 year	59%	43-71	60%	40-75	55%	28-75	0.9	0.4-2.5	0.9
2 years	44%	29-58	38%	20-55	55%	28-75	1.5	0.6-3.5	0.4
last f/up	30%	16-46	19%	5-39	47%	21-69	1.6	0.7-3.7	0.2
PFS, %KM
100 days	85%	71-93	83%	64-93	88%	61-97	1.4	0.3-7.2	0.7
1 year	48%	33-61	47%	28-63	50%	24-72	1.2	0.5-2.8	0.7
2 years	31%	17-45	26%	12-42	43%	19-66	1.7	0.7-3.8	0.2
Last f/up	23%	9-41	13%	1-38	43%	19-66	1.7	0.8-3.6	0.2

Figure legend: ANC-absolute neutrophil count; PLT-platelets; aGVHD- acute graft-versus-host-disease; cGVHD-chronic graft-versus-host-disease; NRM-non-relapse mortality; OS-overall survival; PFS-progression-free survival. % CI cumulative incidence, % KM Kaplan-Meier.